Episódios
-
Kim Perry, Chief Growth Officer at emtelligent, focuses on using medical AI in the prior authorization process to structure unstructured medical text in patient records, making whole record healthcare possible. AI can be used to extract relevant information from faxed or PDF medical records, saving time and improving efficiency over existing manual processes. For payers, there is potential for medical AI to address other processes such as risk adjustment, care management, quality measures, and payment integrity in an environment still lacking interoperability and reliant on highly trained humans.
Kim explains, "For prior authorization in particular, well over 50% of our prior authorizations here in this country are manual. And that means once a prior authorization is submitted for a request for a procedure or a specialty drug, it's a cue for a clinician to review. And part of that review process is to pull a patient's record."
"Unfortunately, because of the lack of interoperability in the healthcare ecosystem, that record is often a fax and a PDF, which could be hundreds of pages. So, the clinician is tasked to manually read through that PDF to find the clinically relevant information to help them deny or approve the prior authorization. So, what they're doing here is using AI to pull out the relevant information at the time that's needed so the clinician doesn't have to manually read through all hundreds of pages looking for the needle in the haystack, if you will, of the information that they're looking for to solve that problem in that point in time."
"I think people assume that with the adoption of EMRs, everything will be digital. But again, due to the lack of interoperability or the lack of payers, in this case, getting direct access into the EMRs for the clinical data, there has to be a way to transmit the information, the relevant information. And often, as I mentioned, it's fax-based. The health systems or the providers are faxing over medical records to the payers. Today, the payers are forced to do that manual review because they haven't had the tools available to them until now to help them apply technology to that manual review process."
#emtelligent #PriorAuthorization #MedicalAI #ArtificialIntelligence #HealthcareInnovations #CMS #LLM #LargeLanguageModels #ClinicalData #EHR #FutureofHealthcare
emtelligent.com
Listen to the podcast here
-
Kim Perry, Chief Growth Officer at emtelligent, focuses on using medical AI in the prior authorization process to structure unstructured medical text in patient records, making whole record healthcare possible. AI can be used to extract relevant information from faxed or PDF medical records, saving time and improving efficiency over existing manual processes. For payers, there is potential for medical AI to address other processes such as risk adjustment, care management, quality measures, and payment integrity in an environment still lacking interoperability and reliant on highly trained humans.
Kim explains, "For prior authorization in particular, well over 50% of our prior authorizations here in this country are manual. And that means once a prior authorization is submitted for a request for a procedure or a specialty drug, it's a cue for a clinician to review. And part of that review process is to pull a patient's record."
"Unfortunately, because of the lack of interoperability in the healthcare ecosystem, that record is often a fax and a PDF, which could be hundreds of pages. So, the clinician is tasked to manually read through that PDF to find the clinically relevant information to help them deny or approve the prior authorization. So, what they're doing here is using AI to pull out the relevant information at the time that's needed so the clinician doesn't have to manually read through all hundreds of pages looking for the needle in the haystack, if you will, of the information that they're looking for to solve that problem in that point in time."
"I think people assume that with the adoption of EMRs, everything will be digital. But again, due to the lack of interoperability or the lack of payers, in this case, getting direct access into the EMRs for the clinical data, there has to be a way to transmit the information, the relevant information. And often, as I mentioned, it's fax-based. The health systems or the providers are faxing over medical records to the payers. Today, the payers are forced to do that manual review because they haven't had the tools available to them until now to help them apply technology to that manual review process."
#emtelligent #PriorAuthorization #MedicalAI #ArtificialIntelligence #HealthcareInnovations #CMS #LLM #LargeLanguageModels #ClinicalData #EHR #FutureofHealthcare
emtelligent.com
Download the transcript here
-
Estão a faltar episódios?
-
Nolan Townsend, CEO of Lexeo Therapeutics, and Jen Farmer, CEO of FARA, the Friedreich's Ataxia Research Alliance, are working together to better understand and treat Friedreich's Ataxia. This rare genetic condition includes cardiomyopathy and scoliosis. Lexeo Therapeutics is studying gene therapy as a potential treatment for the cardiovascular component of the disease. The Friedreich's Ataxia Research Alliance (FARA) plays a role in funding research, understanding the natural history of the disease, and advocating for treatments.
Nolan explains, "For most patients in Friedreich’s ataxia, cardiovascular disease becomes a very challenging component of the pathology, and it is what’s called a hypertrophic cardiomyopathy phenocopy. So, it mimics hypertrophic cardiomyopathy, which is a thickening of the heart wall. And that typically progresses as well, which, for many patients, ends up being the cause of mortality associated with the disease. This pathology does appear to be amenable to treatment approaches like gene therapy, and it’s one that we’re working on here at Lexeo."
Jen elaborates, "As Nolan mentioned, it’s caused by mutations in a gene called FXN, and the mutation in the gene causes a silencing of the gene. So, individuals with FA have what we call frataxin deficiency. And frataxin is a highly conserved protein that is important in lots of different cells, which is why the disease affects multiple organ systems. So, while it’s a genetic disease, it’s this protein deficiency that causes the pathology within the cell. The cells just don’t make enough energy and don’t function properly, and that’s what contributes to the underlying cause of the disease."
#FriedreichsAtaxia #CureFA #FAAwarenessMonth #FAAwarenessDay #RareDiseases
LexeoTX.com
CureFA.org
Listen to the podcast here
-
Nolan Townsend, CEO of Lexeo Therapeutics, and Jen Farmer, CEO of FARA, the Friedreich's Ataxia Research Alliance, are working together to better understand and treat Friedreich's Ataxia. This rare genetic condition includes cardiomyopathy and scoliosis. Lexeo Therapeutics is studying gene therapy as a potential treatment for the cardiovascular component of the disease. The Friedreich's Ataxia Research Alliance (FARA) plays a role in funding research, understanding the natural history of the disease, and advocating for treatments.
Nolan explains, "For most patients in Friedreich’s ataxia, cardiovascular disease becomes a very challenging component of the pathology, and it is what’s called a hypertrophic cardiomyopathy phenocopy. So, it mimics hypertrophic cardiomyopathy, which is a thickening of the heart wall. And that typically progresses as well, which, for many patients, ends up being the cause of mortality associated with the disease. This pathology does appear to be amenable to treatment approaches like gene therapy, and it’s one that we’re working on here at Lexeo."
Jen elaborates, "As Nolan mentioned, it’s caused by mutations in a gene called FXN, and the mutation in the gene causes a silencing of the gene. So, individuals with FA have what we call frataxin deficiency. And frataxin is a highly conserved protein that is important in lots of different cells, which is why the disease affects multiple organ systems. So, while it’s a genetic disease, it’s this protein deficiency that causes the pathology within the cell. The cells just don’t make enough energy and don’t function properly, and that’s what contributes to the underlying cause of the disease."
#FriedreichsAtaxia #CureFA #FAAwarenessMonth #FAAwarenessDay #RareDiseases
LexeoTX.com
CureFA.org
Download the transcript here
-
Dr. Craig Joseph, Chief Medical Officer at Nordic Global, highlights the concerns and challenges healthcare professionals face when using health IT and the clinician burnout related to the administrative burdens of electronic health records. He addresses the obstacles to integrating IT into healthcare workflows, including cost, risk aversion, and resource limitations. He identifies areas where AI can have an immediate impact in reducing errors and biases.
Craig elaborates, "In the past, we lived in a paper-based world, so it was pretty flexible. You could fill out a form or not fill out a form. You could give as much detail or as little detail. Often, especially physicians really couldn't read what they were writing anyway, so it was less important. All of that's changed now in the last 15 or 20 years since the advent of electronic health records."
"What we've seen with large language models, like Chat GPT and other modern AIs, is the ability to do a lot of things with voice now, to be able to communicate directly with a patient, not have to look at the screen to either get information or to write a progress note. Lots of physicians have complained deservedly that they have to spend pajama time, time after they put their kids to bed at night, where they're not getting paid and writing their progress notes and office visit notes."
"I think AI, like LLMs are going to really do a lot to help to rehumanize the interactions that we have. Although, there will be downsides. For that to work, there has to be a microphone in the exam room and it has to be listening to what you and the doctor are saying to one another. Folks are going to have to be comfortable with that to be able to leverage some of those things."
#NordicGlobal #AI #MedicalAI #Hospitals #HealthIT
nordicglobal.com
Listen to the podcast here
-
Dr. Craig Joseph, Chief Medical Officer at Nordic Global, highlights the concerns and challenges healthcare professionals face when using health IT and the clinician burnout related to the administrative burdens of electronic health records. He addresses the obstacles to integrating IT into healthcare workflows, including cost, risk aversion, and resource limitations. He identifies areas where AI can have an immediate impact in reducing errors and biases.
Craig elaborates, "In the past, we lived in a paper-based world, so it was pretty flexible. You could fill out a form or not fill out a form. You could give as much detail or as little detail. Often, especially physicians really couldn't read what they were writing anyway, so it was less important. All of that's changed now in the last 15 or 20 years since the advent of electronic health records."
"What we've seen with large language models, like Chat GPT and other modern AIs, is the ability to do a lot of things with voice now, to be able to communicate directly with a patient, not have to look at the screen to either get information or to write a progress note. Lots of physicians have complained deservedly that they have to spend pajama time, time after they put their kids to bed at night, where they're not getting paid and writing their progress notes and office visit notes."
"I think AI, like LLMs are going to really do a lot to help to rehumanize the interactions that we have. Although, there will be downsides. For that to work, there has to be a microphone in the exam room and it has to be listening to what you and the doctor are saying to one another. Folks are going to have to be comfortable with that to be able to leverage some of those things."
#NordicGlobal #AI #MedicalAI #Hospitals #HealthIT
nordicglobal.com
Download the transcript here
-
Mike Kelly, CEO of NervGen Pharma, discusses the company's vision to build a startup biotech focused on repairing the central nervous system, helping patients regain function, not just slowing progression. Their first product, NVG-291, is currently in clinical trials for spinal cord injury. The drug candidate aims to promote natural repair by targeting molecules called CSPGs that inhibit nerve growth and repair. NerveGen is also developing NVG-300 for other indications such as stroke, ALS, MS, and Alzheimer's. He draws parallels between his previous experience developing the Narcan Nasal Spray for opioid overdose and the unmet medical need in spinal cord injury.
Mike explains, "We are a company focusing on a group of products, more like a platform, that will enable the nervous system to repair itself. So the vision is to build a startup biotech focused in CNS and to get our first product over the line in spinal cord injury."
"There are no drugs available. So this is something that happens in an instant and someone's life has changed forever. The patient typically will then get hospitalized, have surgery to decompress the area that's injured, and then they're on the road to recovery. The only treatment is rehabilitation and exercise, and they push themselves to remake as many connections as possible. Still, that repair typically plateaus around six to nine months after their injury. And the level of function they regained during that period is where they'll be for the rest of their lives, unfortunately."
"NVG-291 is a product that aims to promote natural repair. When you damage, say, you cut your finger or break your foot, your body repairs itself very easily. When you damage your central nervous system, your body protects itself very well and inhibits repair, actually. Our drug targets one of those mechanisms that inhibit repair, turns it off, and allows the body to repair itself naturally."
#NervGenPharma #SCI #SpinalCordInjury #SpinalNews #SpinalInjury #Paralysis #NerveRepair #CNS
NervGen.com
Listen to the podcast here
-
Mike Kelly, CEO of NervGen Pharma, discusses the company's vision to build a startup biotech focused on repairing the central nervous system, helping patients regain function, not just slowing progression. Their first product, NVG-291, is currently in clinical trials for spinal cord injury. The drug candidate aims to promote natural repair by targeting molecules called CSPGs that inhibit nerve growth and repair. NerveGen is also developing NVG-300 for other indications such as stroke, ALS, MS, and Alzheimer's. He draws parallels between his previous experience developing the Narcan Nasal Spray for opioid overdose and the unmet medical need in spinal cord injury.
Mike explains, "We are a company focusing on a group of products, more like a platform, that will enable the nervous system to repair itself. So the vision is to build a startup biotech focused in CNS and to get our first product over the line in spinal cord injury."
"There are no drugs available. So this is something that happens in an instant and someone's life has changed forever. The patient typically will then get hospitalized, have surgery to decompress the area that's injured, and then they're on the road to recovery. The only treatment is rehabilitation and exercise, and they push themselves to remake as many connections as possible. Still, that repair typically plateaus around six to nine months after their injury. And the level of function they regained during that period is where they'll be for the rest of their lives, unfortunately."
"NVG-291 is a product that aims to promote natural repair. When you damage, say, you cut your finger or break your foot, your body repairs itself very easily. When you damage your central nervous system, your body protects itself very well and inhibits repair, actually. Our drug targets one of those mechanisms that inhibit repair, turns it off, and allows the body to repair itself naturally."
#NervGenPharma #SCI #SpinalCordInjury #SpinalNews #SpinalInjury #Paralysis #NerveRepair #CNS
NervGen.com
Download the transcript here
-
Matt Cronin, Founding Partner of House of Kaizen, discusses how patients' changing healthcare expectations are shaped by their experiences with products and services such as Netflix and Amazon Prime. Consumers now expect a longer-term relationship and personalized experiences with their healthcare providers. House of Kaizen emphasizes the importance of building better customer experiences in health and wellness to improve health outcomes and create more value for businesses. In the age of AI, the importance of trust and brand reputation is paramount. Healthcare providers, as the trusted source of information and a filter for web-based searches, play a crucial role in this landscape.
Matt elaborates, "We're a specialized consulting firm for recurring revenue products and services. We build loyalty and advocacy for better lifetime value through customer experience optimization. We do this for all kinds of businesses that operate on a recurring revenue model, which includes many products and services in the health and wellness space. It's a space we've been working in for over 20 years. It's an area where we see a ton of leadership but also a ton of potential in understanding a longer-term customer journey. A true relationship, as opposed to a singular point with the transaction, actually can be a real advantage and an opportunity to set yourself apart from the competitors in the market space."
"When it comes to health and wellness, we have, of course, the healthcare scenario where people have recurring relationships with their physicians, they have recurring relationships with the healthcare systems in which they operate with their insurance companies. But they also have recurring relationships with the products that they may use, like software technology or hardware technology, the news and information that they consume related to their health and wellness, as well as replenishable products like the foods, drinks, supplements, medication, all of those things can make up their portfolio of health and wellness that is a long-term relationship."
#HouseofKaizen #PatientFirst #PatientExperience #HealthcareInnovation #HealthcareMarketing
houseofkaizen.com
Listen to the podcast here
-
Matt Cronin, Founding Partner of House of Kaizen, discusses how patients' changing healthcare expectations are shaped by their experiences with products and services such as Netflix and Amazon Prime. Consumers now expect a longer-term relationship and personalized experiences with their healthcare providers. House of Kaizen emphasizes the importance of building better customer experiences in health and wellness to improve health outcomes and create more value for businesses. In the age of AI, the importance of trust and brand reputation is paramount. Healthcare providers, as the trusted source of information and a filter for web-based searches, play a crucial role in this landscape.
Matt elaborates, "We're a specialized consulting firm for recurring revenue products and services. We build loyalty and advocacy for better lifetime value through customer experience optimization. We do this for all kinds of businesses that operate on a recurring revenue model, which includes many products and services in the health and wellness space. It's a space we've been working in for over 20 years. It's an area where we see a ton of leadership but also a ton of potential in understanding a longer-term customer journey. A true relationship, as opposed to a singular point with the transaction, actually can be a real advantage and an opportunity to set yourself apart from the competitors in the market space."
"When it comes to health and wellness, we have, of course, the healthcare scenario where people have recurring relationships with their physicians, they have recurring relationships with the healthcare systems in which they operate with their insurance companies. But they also have recurring relationships with the products that they may use, like software technology or hardware technology, the news and information that they consume related to their health and wellness, as well as replenishable products like the foods, drinks, supplements, medication, all of those things can make up their portfolio of health and wellness that is a long-term relationship."
#HouseofKaizen #PatientFirst #PatientExperience #HealthcareInnovation #HealthcareMarketing
houseofkaizen.com
Download the transcript here
-
Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene expression and promoting healthy cell development opens the door to potential combination therapy, where menin inhibitors could be layered onto existing treatments for various cancers related to menin independence.
Mollie explains, "In oncology, we have gotten good at treating the end state, but cancer has many, many causes with a common final endpoint to the way the cells look. So, it's many, many different diseases all at once. We've learned and are learning that with better technology and a better understanding of cancer in general we can identify not just how to stop the end state but how to stop it from starting."
"That's where ziftomenib comes in. Ziftomenib addresses key mutations that when they occur, are what cause the development of cancer. So you're able to shut down the development and force the cells to develop normally rather than waiting until they're already diseased and killing them with chemotherapy or some other cytotoxic agent."
"There is a protein complex that we refer to as the menin MLL complex, which goes rogue when something unusual happens in the cell. For example, that could be an NPM1 mutation. That could be a KMT2A rearrangement. Those are two things that are well-known to happen within AML diseases. It could also be a SETD2 RUNX1 mutation. So many types of mutations could happen that could cause this machinery to go rogue within the cell. And that complex causes genes to become active at levels and at times that are abnormal."
#KuraOncology #Ziftomenib #MeninInhibitors #PrecisionMedicine #BTD #AML
KuraOncology.com
Listen to the podcast here
-
Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene expression and promoting healthy cell development opens the door to potential combination therapy, where menin inhibitors could be layered onto existing treatments for various cancers related to menin independence.
Mollie explains, "In oncology, we have gotten good at treating the end state, but cancer has many, many causes with a common final endpoint to the way the cells look. So, it's many, many different diseases all at once. We've learned and are learning that with better technology and a better understanding of cancer in general we can identify not just how to stop the end state but how to stop it from starting."
"That's where ziftomenib comes in. Ziftomenib addresses key mutations that when they occur, are what cause the development of cancer. So you're able to shut down the development and force the cells to develop normally rather than waiting until they're already diseased and killing them with chemotherapy or some other cytotoxic agent."
"There is a protein complex that we refer to as the menin MLL complex, which goes rogue when something unusual happens in the cell. For example, that could be an NPM1 mutation. That could be a KMT2A rearrangement. Those are two things that are well-known to happen within AML diseases. It could also be a SETD2 RUNX1 mutation. So many types of mutations could happen that could cause this machinery to go rogue within the cell. And that complex causes genes to become active at levels and at times that are abnormal."
#KuraOncology #Ziftomenib #MeninInhibitors #PrecisionMedicine #BTD #AML
KuraOncology.com
Download the transcript here
-
Dr. Steffen-Sebastian Bolz, Chief Scientific Officer of Swiss-based Aphaia Pharma, shines a light on the excitement around weight loss drugs due to the discovery that GLP-1 agonists and points out the shift in the perception of obesity as a root cause of various health issues. Aphaia Pharma's approach involves stimulating hormone production in the small intestine by reinvigorating the mechanism that has become dormant due to the ingestion of highly refined foods. The company is also exploring the effects of the circadian rhythm on weight loss and maintaining a healthy weight.
Steffen elaborates, "What is understood now is obesity is the root cause of many sequel pathologies like type 2 diabetes, diabetes, fatty liver disease, and a whole lot of cardiovascular disease. So, the idea is that if we get obesity under control and the obesity pandemic under control, we might also lower the incidence of all the other diseases. There’s a massive rush into this field because there are already blockbuster drugs in the market, as you just said, and there are already 1 billion people worldwide who are obese and our projections predict that rapid growth of these numbers. So this is kind of the gold rush."
"Let me start with briefly outlining the mode of action of GLP-1 agonists. A common denominator of all metabolic diseases, either obesity or a related disease, is a lack of hormone output from the small intestine. What’s behind this is that the small intestine is capable of producing hormones in response to food intake."
"All these hormones act in an orchestrated fashion to allow digestion, proper immune control, and all these things. It was found that all these hormones are reduced in patients with obesity, and GLP-1 agonists replace one of those hormones, GLP-1. They do this by injecting very high doses to yield the effects we’re seeing, such as type 2 diabetes control and weight loss. But that’s just the hormone replacement therapy. That’s just one hormone out of a large portfolio, out of hundreds of hormones produced by the small intestine. And that is exactly where our thought process started."
#AphaiaPharma #Obesity #GLP1Agonists #SmallIntestine #WeightLoss
AphaiaPharma.com
Listen to the podcast here
-
Dr. Steffen-Sebastian Bolz, Chief Scientific Officer of Swiss-based Aphaia Pharma, shines a light on the excitement around weight loss drugs due to the discovery that GLP-1 agonists and points out the shift in the perception of obesity as a root cause of various health issues. Aphaia Pharma's approach involves stimulating hormone production in the small intestine by reinvigorating the mechanism that has become dormant due to the ingestion of highly refined foods. The company is also exploring the effects of the circadian rhythm on weight loss and maintaining a healthy weight.
Steffen elaborates, "What is understood now is obesity is the root cause of many sequel pathologies like type 2 diabetes, diabetes, fatty liver disease, and a whole lot of cardiovascular disease. So, the idea is that if we get obesity under control and the obesity pandemic under control, we might also lower the incidence of all the other diseases. There’s a massive rush into this field because there are already blockbuster drugs in the market, as you just said, and there are already 1 billion people worldwide who are obese and our projections predict that rapid growth of these numbers. So this is kind of the gold rush."
"Let me start with briefly outlining the mode of action of GLP-1 agonists. A common denominator of all metabolic diseases, either obesity or a related disease, is a lack of hormone output from the small intestine. What’s behind this is that the small intestine is capable of producing hormones in response to food intake."
"All these hormones act in an orchestrated fashion to allow digestion, proper immune control, and all these things. It was found that all these hormones are reduced in patients with obesity, and GLP-1 agonists replace one of those hormones, GLP-1. They do this by injecting very high doses to yield the effects we’re seeing, such as type 2 diabetes control and weight loss. But that’s just the hormone replacement therapy. That’s just one hormone out of a large portfolio, out of hundreds of hormones produced by the small intestine. And that is exactly where our thought process started."
#AphaiaPharma #Obesity #GLP1Agonists #SmallIntestine #WeightLoss
AphaiaPharma.com
Download the transcript here
-
Rick Vanzura, CEO of Freight Farms, and Dr. Amber Orman, Chief Wellness Officer at Advent Health, discuss their partnership in bringing hyperlocal, sustainable food to healthcare facilities. Freight Farms uses modified shipping containers to grow crops, allowing for year-round production with minimal land and water usage. Advent Health recognized the importance of nutrition in whole-person care and saw the opportunity to provide their team members, physicians, patients, and the public with fresh, nutritious food and donate to local food pantries. The partnership has demonstrated the power of food as medicine and the potential for sustainable farming practices in healthcare settings.
Rick explains, "We grow about two and a half to three acres worth of crops out of an 8 by 40-foot shipping container. It looks like any shipping container you would see on a dock or a boat, but it's highly modified to grow food using LED lights, airflow, nutrients delivered through the farm, and controlled through software. It's really designed so you can grow 365 days a year, very clean food, with temperatures from minus 40° to 120°, and do that consistently. And again, get all of the value of it being hyperlocal and fresh and using minimal land and water."
Amber elaborates," We have a doctors’ lounge where the doctors, nurse practitioners, and some leaders eat. We also have a public-facing cafeteria, so anybody who visits the hospital can eat in the cafeteria. It's served in there. It's served in our patient meals, so we have certain meals containing the produce, so all of our salads, sandwiches, and wraps. Then we're also supplying anything extra to a local food pantry, and then they also donate to Kingdom Kids Academy in Kissimmee. We are able to sustain all of these things and donate some extra when we have it, even out to the community. It certainly provides better nutrition within a given day to those patients and team members and the people who receive the donations. It's also a way to start educating people about the benefits of eating more plants. We all need to eat more plants for better health, and so that's one of our guiding missions here."
#AdventHealth #FreightFarms #VerticalFarming #Healthcare #FoodAsMedicine #AgTech
adventhealth.com
freightfarms.com
Listen to the podcast here
-
Rick Vanzura, CEO of Freight Farms, and Dr. Amber Orman, Chief Wellness Officer at Advent Health, discuss their partnership in bringing hyperlocal, sustainable food to healthcare facilities. Freight Farms uses modified shipping containers to grow crops, allowing for year-round production with minimal land and water usage. Advent Health recognized the importance of nutrition in whole-person care and saw the opportunity to provide their team members, physicians, patients, and the public with fresh, nutritious food and donate to local food pantries. The partnership has demonstrated the power of food as medicine and the potential for sustainable farming practices in healthcare settings.
Rick explains, "We grow about two and a half to three acres worth of crops out of an 8 by 40-foot shipping container. It looks like any shipping container you would see on a dock or a boat, but it's highly modified to grow food using LED lights, airflow, nutrients delivered through the farm, and controlled through software. It's really designed so you can grow 365 days a year, very clean food, with temperatures from minus 40° to 120°, and do that consistently. And again, get all of the value of it being hyperlocal and fresh and using minimal land and water."
Amber elaborates," We have a doctors’ lounge where the doctors, nurse practitioners, and some leaders eat. We also have a public-facing cafeteria, so anybody who visits the hospital can eat in the cafeteria. It's served in there. It's served in our patient meals, so we have certain meals containing the produce, so all of our salads, sandwiches, and wraps. Then we're also supplying anything extra to a local food pantry, and then they also donate to Kingdom Kids Academy in Kissimmee. We are able to sustain all of these things and donate some extra when we have it, even out to the community. It certainly provides better nutrition within a given day to those patients and team members and the people who receive the donations. It's also a way to start educating people about the benefits of eating more plants. We all need to eat more plants for better health, and so that's one of our guiding missions here."
#AdventHealth #FreightFarms #VerticalFarming #Healthcare #FoodAsMedicine #AgTech
adventhealth.com
freightfarms.com
Download the transcript here
-
Guang Qu, Co-Founder of NGGT Corporation is focused on developing gene therapy products using dual functional vector strategies. Guang highlights the importance of distinguishing between recessive and dominant mutations in rare diseases and explains how their approach differs from other gene therapy approaches. The two leading indications caused by a gene mutation that NGGT is working on are Bietti's Crystalline Dystrophy (BCD), a rare ocular disease, and phenylketonuria (PKU), a metabolic disease.
Guang explains, "For our strategies and our product development strategies, I think we are leveraging our experience in the gene therapy field. Later, I will talk more about myself, Dr. Lixin Jiang, and our team. The other thing we are leveraging is our fully integrated team in gene therapy product development, which involves R&D, research and development, CGMP manufacturers, from tox development and clinical regulatory functions and the medical teams. So with all of the teams we built up in the last couple of years, we're in very good positions in developing our gene therapy products."
"So, of the two currently leading indications, one is involved in ocular disease, what we call the BCD, Bietti's Crystalline Dystrophy. This disease is caused by a gene mutation. The gene mutation causes lipid metabolic problems. The particular gene is called the CYP4V2 gene. The mutation directly leads to the lipid metabolic process being interrupted. Therefore, lipids are precipitated in the different ocular cells, such as the cornea and the retina. That's most of the disease cell layers affected."
#AAV #GeneEditing #GeneTherapy #PKU #BCD
Listen to the podcast here
-
Guang Qu, Co-Founder of NGGT Corporation is focused on developing gene therapy products using dual functional vector strategies. Guang highlights the importance of distinguishing between recessive and dominant mutations in rare diseases and explains how their approach differs from other gene therapy approaches. The two leading indications caused by a gene mutation that NGGT is working on are Bietti's Crystalline Dystrophy (BCD), a rare ocular disease, and phenylketonuria (PKU), a metabolic disease.
Guang explains, "For our strategies and our product development strategies, I think we are leveraging our experience in the gene therapy field. Later, I will talk more about myself, Dr. Lixin Jiang, and our team. The other thing we are leveraging is our fully integrated team in gene therapy product development, which involves R&D, research and development, CGMP manufacturers, from tox development and clinical regulatory functions and the medical teams. So with all of the teams we built up in the last couple of years, we're in very good positions in developing our gene therapy products."
"So, of the two currently leading indications, one is involved in ocular disease, what we call the BCD, Bietti's Crystalline Dystrophy. This disease is caused by a gene mutation. The gene mutation causes lipid metabolic problems. The particular gene is called the CYP4V2 gene. The mutation directly leads to the lipid metabolic process being interrupted. Therefore, lipids are precipitated in the different ocular cells, such as the cornea and the retina. That's most of the disease cell layers affected."
#AAV #GeneEditing #GeneTherapy #PKU #BCD
Download the transcript here
-
Jennifer Jones-McMeans, divisional vice president of global clinical affairs at Abbott’s vascular business, and Dr. Brian DeRubertis, a doctor at the New York-Presbyterian Weill Cornell Medical Center, shine a light on peripheral artery disease and critical limb-threatening ischemia where artery blockage restricts blood flow to the lower legs. Abbott has developed the Esprit, a dissolving scaffold that opens up the artery in the blocked area and elutes a drug that slows disease progression. Their LIFE-BTK trial demonstrated success in a diverse patient population and is a significant new treatment option for CLTI.
Brian explains, "One of the things that I’ll say is our group is starting to explore doing additional efforts at patient education with our own patients, patients who have actually been diagnosed with this disease, and educating them a little bit more about what it means to have this disease, how they can be involved in the process of trying to prevent their disease from getting worse. And the reason we’re doing this is exactly what you said. Everyone knows what a heart attack is, but very few people understand that the same process that leads to clogged arteries in the heart or blocked arteries in the heart can lead to blocked arteries in the legs. Those blockages can ultimately lead to amputation. And so, the education of patients and keeping them informed about the disease process is one important part of this."
Jennifer elaborates, "This is really a landmark moment for people with this severe form of peripheral artery disease, which we’re calling CLTI. When you think of these minimally invasive procedures to treat this disease, currently in the United States, you only have plain balloon angioplasty. And this is what the LIFE BTK trial was measured against. The Esprit was measured, which is our dissolving stent, and tested against the standard of care, plain balloon angioplasty. And it’s been decades since there’s been any innovation in this, what they sometimes call the endovascular first space. The Esprit is made out of a polymer material similar to what you would think about with dissolving stitches, and it also has a drug on it."
#Abbott #CLTI #PeripheralArteryDisease #PAD #LegArteries #PlainBalloonAngioplasty #DiversityinClinicalTrials
abbott.com
Listen to the podcast here
-
Jennifer Jones-McMeans, divisional vice president of global clinical affairs at Abbott’s vascular business, and Dr. Brian DeRubertis, a doctor at the New York-Presbyterian Weill Cornell Medical Center, shine a light on peripheral artery disease and critical limb-threatening ischemia where artery blockage restricts blood flow to the lower legs. Abbott has developed the Esprit, a dissolving scaffold that opens up the artery in the blocked area and elutes a drug that slows disease progression. Their LIFE-BTK trial demonstrated success in a diverse patient population and is a significant new treatment option for CLTI.
Brian explains, "One of the things that I’ll say is our group is starting to explore doing additional efforts at patient education with our own patients, patients who have actually been diagnosed with this disease, and educating them a little bit more about what it means to have this disease, how they can be involved in the process of trying to prevent their disease from getting worse. And the reason we’re doing this is exactly what you said. Everyone knows what a heart attack is, but very few people understand that the same process that leads to clogged arteries in the heart or blocked arteries in the heart can lead to blocked arteries in the legs. Those blockages can ultimately lead to amputation. And so, the education of patients and keeping them informed about the disease process is one important part of this."
Jennifer elaborates, "This is really a landmark moment for people with this severe form of peripheral artery disease, which we’re calling CLTI. When you think of these minimally invasive procedures to treat this disease, currently in the United States, you only have plain balloon angioplasty. And this is what the LIFE BTK trial was measured against. The Esprit was measured, which is our dissolving stent, and tested against the standard of care, plain balloon angioplasty. And it’s been decades since there’s been any innovation in this, what they sometimes call the endovascular first space. The Esprit is made out of a polymer material similar to what you would think about with dissolving stitches, and it also has a drug on it."
#Abbott #CLTI #PeripheralArteryDisease #PAD #LegArteries #PlainBalloonAngioplasty #DiversityinClinicalTrials
abbott.com
Download the transcript here
- Mostrar mais
